SCHEMBL25835596

SCHEMBL25835596

Cc1ccc(C(OC(=O)CCOCCN)(c2ccccc2)c2ccccc2Cl)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 11/20 0.36
HTR1A P08908 2/20 0.35
ADRA2A P08913 2/20 0.35
CHRM1 P11229 2/20 0.35
DRD1 P21728 2/20 0.35
TBXA2R P21731 2/20 0.35
SLC6A2 P23975 2/20 0.35
ADRA1A P35348 2/20 0.35
OPRM1 P35372 2/20 0.35
DRD3 P35462 2/20 0.35
SLC6A3 Q01959 2/20 0.35
KCNH2 Q12809 2/20 0.35
KCNK2 O95069 1/20 0.35
ABCB11 O95342 1/20 0.35
ADRB2 P07550 1/20 0.35
ABCB1 P08183 1/20 0.35
ADORA3 P0DMS8 1/20 0.35
ADRB3 P13945 1/20 0.35
DRD2 P14416 1/20 0.35
ADRA2C P18825 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25835595 0.99 KIF11 (0.35) KIF11HTR1AADRA2ACHRM1DRD1
SCHEMBL26032939 0.92 HDAC3 (0.43) HTR1AADRA2ACHRM1DRD1TBXA2R
SCHEMBL26811331 0.91 KIF11 (0.40) KIF11ADRA1AKCNH2HTR2AHTR2C
SCHEMBL25835599 0.91 HDAC3 (0.43) HTR1AADRA2ACHRM1DRD1TBXA2R
SCHEMBL17929803 0.90 KIF11 (0.35) KIF11HTR1AADRA2ACHRM1DRD1
SCHEMBL13254135 0.86 KIF11 (0.41) KIF11KCNH2HDAC3HDAC1KCNN4
SCHEMBL15761354 0.85 KIF11 (0.39) KIF11ADRA1AKCNH2HTR2AHTR2C
SCHEMBL25846323 0.83 KIF11 (0.40) KIF11CYP3A4MAPT
SCHEMBL25846388 0.83 KIF11 (0.40) KIF11CYP3A4MAPT
SCHEMBL26045321 0.83 KIF11 (0.40) KIF11CYP3A4MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF Arrowhead Pharmaceuticals, Inc. 2023-08-24 US disclosed
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS Arrowhead Pharmaceuticals, Inc. 2023-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230226193-A1 LIPID CONJUGATES FOR THE DELIVERY OF THERAPEUTIC AGENTS CPT1B, MUSK, MYLK2 KIF11 367/4885HTR1A 4777/4885ADRA2A 2569/4885
US-20230265429-A1 SKELETAL MUSCLE DELIVERY PLATFORMS AND METHODS OF USE THEREOF MUSK, MYLK2, TNNC1 KIF11 939/4885HTR1A 4806/4885ADRA2A 415/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.